Achillion Pharmaceuticals Inc. (ACHN) News Nov 20,
Post# of 250663
Posted On: 11/20/2014 6:59:15 PM
Achillion Pharmaceuticals Inc. (ACHN) News Nov 20, 2014, 5:14 p.m.
MarketWatch News on ACHN
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
6 stocks to watch 2:10 p.m. Oct. 22, 2014 - The Trading Deck
6 stocks to watch 2:36 p.m. Oct. 9, 2014 - The Trading Deck
10 Nasdaq stocks with returns of at least 240% in 2014 4:38 p.m. Sept. 11, 2014 - Philip van Doorn
5 stocks to watch 12:38 p.m. Sept. 3, 2014 - The Trading Deck
Six stocks to watch 12:47 p.m. Aug. 27, 2014 - The Trading Deck
S&P 500 reaches firmer technical ground 10:30 a.m. Aug. 18, 2014 - Michael Ashbaugh
Stocks trim Ukraine-inspired fall, post weekly gain 3:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 8:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 9:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 7:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 4:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 4:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 2:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 4:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 8:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 9:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 3:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 9:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 9:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Other News on ACHN
Regulus To See Further Declines 10:30 a.m. Nov. 19, 2014 - Seeking Alpha
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook 1:00 a.m. Nov. 19, 2014 - Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews 1:00 a.m. Nov. 19, 2014 - Zacks.com
2 Skyrocketing Biotech Stocks In A Stalling Market 10:33 a.m. Nov. 17, 2014 - benzinga.com
5 Momentum Stocks Currently on the Move with More Potential Upside 12:34 p.m. Nov. 13, 2014 - TheStreet.com
4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic 8:38 a.m. Nov. 13, 2014 - 247WallSt.com
Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? - Tale of the Tape 7:25 a.m. Nov. 13, 2014 - Zacks.com
Deutsche Bank Mystified By 18% Jump In Achillion Pharmaceuticals 7:21 a.m. Nov. 13, 2014 - benzinga.com
Achillion Pharmaceuticals: Still Bullish, But Taking Profits 5:06 p.m. Nov. 12, 2014 - Seeking Alpha
Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results 11:57 a.m. Nov. 12, 2014 - TheStreet.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Hottest Healthcare Stocks Now – ACHN ICUI MYGN SGEN 6:30 a.m. Nov. 12, 2014 - InvestorPlace.com
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog 5:10 p.m. Nov. 11, 2014 - Zacks.com
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About 11:13 a.m. Nov. 11, 2014 - Seeking Alpha
Gilead presents Harvoni data 11:03 a.m. Nov. 11, 2014 - Seeking Alpha
AbbVie presents HCV/HIV and liver transplant HCV data 10:07 a.m. Nov. 11, 2014 - Seeking Alpha
Merck presents data from its investigational HCV combo 9:37 a.m. Nov. 11, 2014 - Seeking Alpha
Gilead presents data from three HCV drug combo studies 9:05 a.m. Nov. 11, 2014 - Seeking Alpha
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape 8:44 a.m. Nov. 11, 2014 - Zacks.com
Merck Down On Hepatitis C Data; Gilead Rises 10:14 a.m. Nov. 10, 2014 - Investors Business Daily
Press Releases on ACHN
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. Nov. 11, 2014 - PR Newswire - PRF
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) 9:02 a.m. Nov. 8, 2014 - GlobeNewswire
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology 9:02 a.m. Nov. 6, 2014 - GlobeNewswire
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics 8:45 a.m. Nov. 4, 2014 - PR Newswire - PRF
Achillion Reports Third Quarter and Nine Month 2014 Financial Results 6:31 a.m. Nov. 4, 2014 - GlobeNewswire
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver 8:31 a.m. Oct. 27, 2014 - PR Newswire - PRF
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 9:24 a.m. Oct. 8, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Dreamworks Animation, SunEdison, El Pollo Loco and Whole Foods Market Released By InvestorsObserver 8:31 a.m. Sept. 30, 2014 - PR Newswire - PRF
Biotech Stocks Technical Data - Medivation, Galectin Therapeutics, Ironwood Pharma, Achillion Pharma, and PDL BioPharma 8:05 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For Achillion Pharmaceuticals, LightInTheBox, VoxelJet, Whole Foods Market and Disney Released By InvestorsObserver 8:31 a.m. Sept. 15, 2014 - PR Newswire - PRF
Technical Updates, Operational Milestones, Product Upgrades, and Energy Saving Programs - Research Reports on Achillion, DE, Honeywell, Lockheed Martin and L-3 Communications 7:35 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 8:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel 7:55 a.m. Sept. 2, 2014 - PR Newswire - PRF
Critical Alerts For Achillion Pharmaceuticals, Intel, YY, JA Solar and Skullcandy Released By InvestorsObserver 8:31 a.m. Aug. 26, 2014 - PR Newswire - PRF
Biotechnology Stocks to Keep an Eye On 8:02 a.m. Aug. 20, 2014 - ACCESSWIRE
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo 7:40 a.m. Aug. 20, 2014 - PR Newswire - PRF
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors 3:06 p.m. Aug. 19, 2014 - GlobeNewswire
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
6:00 a.m. Aug. 15, 2014 - GlobeNewswire
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 7:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 3:06 p.m. Aug. 7, 2014 - GlobeNewswire
MarketWatch News on ACHN
6 stocks to watch 1:35 p.m. Oct. 29, 2014 - The Trading Deck
6 stocks to watch 2:10 p.m. Oct. 22, 2014 - The Trading Deck
6 stocks to watch 2:36 p.m. Oct. 9, 2014 - The Trading Deck
10 Nasdaq stocks with returns of at least 240% in 2014 4:38 p.m. Sept. 11, 2014 - Philip van Doorn
5 stocks to watch 12:38 p.m. Sept. 3, 2014 - The Trading Deck
Six stocks to watch 12:47 p.m. Aug. 27, 2014 - The Trading Deck
S&P 500 reaches firmer technical ground 10:30 a.m. Aug. 18, 2014 - Michael Ashbaugh
Stocks trim Ukraine-inspired fall, post weekly gain 3:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 8:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 9:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 7:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 4:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 4:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 2:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 4:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 8:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 9:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 3:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 9:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 9:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Other News on ACHN
Regulus To See Further Declines 10:30 a.m. Nov. 19, 2014 - Seeking Alpha
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook 1:00 a.m. Nov. 19, 2014 - Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews 1:00 a.m. Nov. 19, 2014 - Zacks.com
2 Skyrocketing Biotech Stocks In A Stalling Market 10:33 a.m. Nov. 17, 2014 - benzinga.com
5 Momentum Stocks Currently on the Move with More Potential Upside 12:34 p.m. Nov. 13, 2014 - TheStreet.com
4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic 8:38 a.m. Nov. 13, 2014 - 247WallSt.com
Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? - Tale of the Tape 7:25 a.m. Nov. 13, 2014 - Zacks.com
Deutsche Bank Mystified By 18% Jump In Achillion Pharmaceuticals 7:21 a.m. Nov. 13, 2014 - benzinga.com
Achillion Pharmaceuticals: Still Bullish, But Taking Profits 5:06 p.m. Nov. 12, 2014 - Seeking Alpha
Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results 11:57 a.m. Nov. 12, 2014 - TheStreet.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Hottest Healthcare Stocks Now – ACHN ICUI MYGN SGEN 6:30 a.m. Nov. 12, 2014 - InvestorPlace.com
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog 5:10 p.m. Nov. 11, 2014 - Zacks.com
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About 11:13 a.m. Nov. 11, 2014 - Seeking Alpha
Gilead presents Harvoni data 11:03 a.m. Nov. 11, 2014 - Seeking Alpha
AbbVie presents HCV/HIV and liver transplant HCV data 10:07 a.m. Nov. 11, 2014 - Seeking Alpha
Merck presents data from its investigational HCV combo 9:37 a.m. Nov. 11, 2014 - Seeking Alpha
Gilead presents data from three HCV drug combo studies 9:05 a.m. Nov. 11, 2014 - Seeking Alpha
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape 8:44 a.m. Nov. 11, 2014 - Zacks.com
Merck Down On Hepatitis C Data; Gilead Rises 10:14 a.m. Nov. 10, 2014 - Investors Business Daily
Press Releases on ACHN
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. Nov. 11, 2014 - PR Newswire - PRF
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) 9:02 a.m. Nov. 8, 2014 - GlobeNewswire
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology 9:02 a.m. Nov. 6, 2014 - GlobeNewswire
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics 8:45 a.m. Nov. 4, 2014 - PR Newswire - PRF
Achillion Reports Third Quarter and Nine Month 2014 Financial Results 6:31 a.m. Nov. 4, 2014 - GlobeNewswire
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver 8:31 a.m. Oct. 27, 2014 - PR Newswire - PRF
Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 9:24 a.m. Oct. 8, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Dreamworks Animation, SunEdison, El Pollo Loco and Whole Foods Market Released By InvestorsObserver 8:31 a.m. Sept. 30, 2014 - PR Newswire - PRF
Biotech Stocks Technical Data - Medivation, Galectin Therapeutics, Ironwood Pharma, Achillion Pharma, and PDL BioPharma 8:05 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For Achillion Pharmaceuticals, LightInTheBox, VoxelJet, Whole Foods Market and Disney Released By InvestorsObserver 8:31 a.m. Sept. 15, 2014 - PR Newswire - PRF
Technical Updates, Operational Milestones, Product Upgrades, and Energy Saving Programs - Research Reports on Achillion, DE, Honeywell, Lockheed Martin and L-3 Communications 7:35 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 8:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel 7:55 a.m. Sept. 2, 2014 - PR Newswire - PRF
Critical Alerts For Achillion Pharmaceuticals, Intel, YY, JA Solar and Skullcandy Released By InvestorsObserver 8:31 a.m. Aug. 26, 2014 - PR Newswire - PRF
Biotechnology Stocks to Keep an Eye On 8:02 a.m. Aug. 20, 2014 - ACCESSWIRE
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo 7:40 a.m. Aug. 20, 2014 - PR Newswire - PRF
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors 3:06 p.m. Aug. 19, 2014 - GlobeNewswire
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
6:00 a.m. Aug. 15, 2014 - GlobeNewswire Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 7:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 3:06 p.m. Aug. 7, 2014 - GlobeNewswire
(0)
(0)